Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

16.7%

1 terminated out of 6 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

5Total
P 1 (4)
P 2 (1)

Trial Status

Not Yet Recruiting2
Recruiting2
Active Not Recruiting1
Terminated1

Clinical Trials (6)

Showing 6 of 6 trials
NCT06723236Phase 1Recruiting

A Study of MGC028 in Participants With Advanced Solid Tumors

NCT07277413Phase 1RecruitingPrimary

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT03252938Phase 1Active Not Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

NCT07374419Phase 1Not Yet RecruitingPrimary

Atamparib in Patients With Advanced Solid Tumors

NCT06951399Phase 2Not Yet Recruiting

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

NCT02121899Terminated

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

Showing all 6 trials

Research Network

Activity Timeline